Streetbeat News

Regulatory

SPY

The Core CPI (MoM) for September has met the estimated value of 0.3%.

Portfolio Pulse from Bill Haddad

October 12, 2023 | 12:30 pm

HSAI

OUST

The U.S. International Trade Commission (ITC) has terminated a patent infringement investigation initiated by Ouster (NYSE:OUST) against Hesai Group (NASDAQ:HSAI). The ITC confirmed Hesai's motion to terminate the investigation, affirming that Ouster's allegations were baseless. Hesai has accused Ouster of spreading false information about Hesai's lidar products and its ties to the Chinese government.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 12:20 pm

BTCUSD

A project known as 'Project Spartacus' aims to inscribe the Afghan War Diary, which Julian Assange is accused of illegally providing to journalists, onto the Bitcoin blockchain. The project uses the Ordinals protocol, a meta protocol for Bitcoin that allows for the addition of arbitrary data to the blockchain. The project aims to combat information censorship and protect the data that Assange risked his life to make public.

Portfolio Pulse from Mehab Qureshi

October 12, 2023 | 12:14 pm

ONTX

Onconova Therapeutics, Inc. (NASDAQ:ONTX) announced that a late-breaking abstract studying rigosertib in patients with recessive dystrophic epidermolysis bullosa (RDEB), associated with advanced/metastatic squamous cell carcinoma (SCC), will be presented at the European Academy of Dermatology and Venereology (EADV). The abstract outlines promising results from a study of four patients treated with rigosertib. Two patients achieved complete cutaneous responses of 12 months or more, one patient experienced metastatic disease progression, and one patient remains on study.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 12:09 pm

ANVS

Annovis Bio Inc. has announced that the interim analysis of their Alzheimer's Disease (AD) trial, based on 107 patients at 6 weeks, has shown positive results. The trial will continue as planned with the same size to maintain the statistical power for both co-primary endpoints.

Portfolio Pulse from Bill Haddad

October 12, 2023 | 12:06 pm

VTAK

Catheter Precision's VIVO, a cardiac mapping system, is now eligible for national reimbursement in the U.K. This could potentially increase the product's sales and usage in the country.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 12:05 pm

INAB

IN8bio, Inc. (NASDAQ:INAB) has completed enrollment in the Phase 1 study of INB-100 in leukemia patients and initiated patient enrollment in the Phase 2 clinical trial evaluating INB-400 in newly diagnosed glioblastoma multiforme (GBM). The company's CEO, William Ho, expressed optimism about the potential of gamma-delta T cells as a treatment option for both solid and hematological cancers. INB-400 was granted Orphan Drug Designation by the FDA in April 2023.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 12:03 pm

ILMN

Illumina Inc (NASDAQ:ILMN) is considering divesting its acquisition of Grail if it loses the final appeals in U.S. or European courts. The company completed its $7.1 billion takeover of Grail in August 2021, despite opposition from regulators. If it wins both cases, it will reassess Grail's assets, which might result in integrating or divesting part or the entire unit. The U.S. Federal Trade Commission (FTC) and the EU have ordered Illumina to divest Grail, which Illumina appealed against.

Portfolio Pulse from Vandana Singh

October 12, 2023 | 11:38 am

NVO

Germany's federal drug regulator, BfArM, has warned pharmacies and drug distributors about counterfeit batches of Novo Nordisk's diabetes medication, Ozempic. The counterfeit injection pens closely resemble the authentic ones in terms of packaging. The regulator has assumed control of the investigation and has called upon distributors and pharmacies to exercise extreme caution. Novo Nordisk also faces significant challenges in ramping up production to meet the overwhelming demand for Ozempic and the weight-loss drug Wegovy.

Portfolio Pulse from Vandana Singh

October 12, 2023 | 11:36 am

OFIX

Orthofix Medical has announced the 510K clearance and full commercial launch of OsteoCove, an advanced bioactive synthetic graft. This development could potentially boost the company's revenues and market share in the medical devices sector.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 11:30 am